Key Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$136K Sell
179
-31
-15% -$23.4K 0.02% 361
2026
Q2
$131K Hold
210
– – 0.02% 376
2026
Q1
$162K Hold
210
– – 0.03% 321
2025
Q4
$162K Sell
210
-71
-25% -$48.2K 0.03% 326
2025
Q3
$169K Sell
281
-26
-8% -$14.7K 0.03% 317
2025
Q2
$161K Hold
307
– – 0.03% 311
2025
Q1
$195K Hold
307
– – 0.04% 270
2024
Q4
$219K Hold
307
– – 0.05% 241
2024
Q3
$323K Buy
307
+1
+0.3% +$1.11K 0.07% 200
2024
Q2
$322K Hold
306
– – 0.08% 185
2024
Q1
$295K Hold
306
– – 0.08% 187
2023
Q4
$269K Hold
306
– – 0.07% 188
2023
Q3
$252K Hold
306
– – 0.08% 179
2023
Q2
$220K Buy
306
+35
+13% +$27K 0.07% 197
2023
Q1
$223K Buy
271
+195
+257% +$147K 0.08% 183
2022
Q4
$52.4K Hold
76
– – 0.02% 351
2022
Q3
$52K Hold
76
– – 0.02% 355
2022
Q2
$45K Hold
76
– – 0.02% 381
2022
Q1
$53K Buy
76
+71
+1,420% +$44.9K 0.03% 354
2021
Q4
$3K Buy
+5
New +$3.07K ﹤0.01% 791
2020
Q2
– Sell
-105
Closed -$50K – 501
2020
Q1
$50K Buy
+105
New +$43.3K 0.05% 212

Other funds holding REGN

Key Financial's REGN Position: Q3 2026 in Review

Key Financial reduced its Regeneron Pharmaceuticals (REGN) stake by 15% in Q3 2026, selling an estimated $23.4K and leaving 179 shares worth $136K. The position accounts for 0.02% of the portfolio, ranked #361.

Key Financial first reported a position in REGN in Q1 2020 and has held it in 21 quarters since. The position peaked at $323K in Q3 2024. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Key Financial held 179 shares of Regeneron Pharmaceuticals worth $136K as of Q3 2026.
  • Key Financial sold 31 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $23.4K.
  • Regeneron Pharmaceuticals made up 0.02% of Key Financial's portfolio in Q3 2026, its #361 holding.
  • Key Financial first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 21 quarters since.
  • Key Financial's Regeneron Pharmaceuticals position peaked at $323K in Q3 2024.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Key Financial's 13F filing for Q3 2026, filed 2 Nov 2026.